🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Kyle J. Seamon

Revolution Medicines (United States)

ORCID: 0009-0005-5028-3752
Biochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

326 citations

Bianca J. Lee, Jingjing Jiang, Aidan C.A. Tomlinson, Kyle J. Seamon, Alessia Mira +48 more

237 citations

Kyle J. Seamon, Yulei Zhao, Yu Chi Yang, Jim Cregg, Dong-Sung Kim +31 more

32 citations

Kyle J. Seamon, Edwin A. Saada, Joshua D. Podlevsky, Steven S. Branda, Jerilyn A. Timlin +2 more

15 citations

Anthony S. Gizzi, Junru Cui, Matthew Egleston, Kyle J. Seamon, Michael DePasquale +4 more

0 citations

Nicole Nasholm, Chiara Ambrogio, Anthony N. Milin, Yang Liu, Elsa Quintana +48 more